Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in resectable early stage non-small cell lung cancer
NCT04025879Phase 3Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2019
- Primary completion
- Jul 2023
- Modality
- Monoclonal Antibodies
- Countries
- 22
01
Overview
A Phase 3 trial of nivolumab in non-small cell lung cancer (NSCLC), sponsored by Bristol Myers Squibb. Started Nov 2019; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04025879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04025879.